APA (7th ed.) Citation

Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., . . . Sever, P. (2017). Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet (British edition), 389(10088), 2473-2481. https://doi.org/10.1016/S0140-6736(17)31075-9

Chicago Style (17th ed.) Citation

Gupta, Ajay, David Thompson, Andrew Whitehouse, Tim Collier, Bjorn Dahlof, Neil Poulter, Rory Collins, and Peter Sever. "Adverse Events Associated with Unblinded, but Not with Blinded, Statin Therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): A Randomised Double-blind Placebo-controlled Trial and Its Non-randomised Non-blind Extension Phase." The Lancet (British Edition) 389, no. 10088 (2017): 2473-2481. https://doi.org/10.1016/S0140-6736(17)31075-9.

MLA (9th ed.) Citation

Gupta, Ajay, et al. "Adverse Events Associated with Unblinded, but Not with Blinded, Statin Therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): A Randomised Double-blind Placebo-controlled Trial and Its Non-randomised Non-blind Extension Phase." The Lancet (British Edition), vol. 389, no. 10088, 2017, pp. 2473-2481, https://doi.org/10.1016/S0140-6736(17)31075-9.